Compare RAVE & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | JSPR |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 43.7M |
| IPO Year | N/A | N/A |
| Metric | RAVE | JSPR |
|---|---|---|
| Price | $3.19 | $1.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.13 |
| AVG Volume (30 Days) | 38.2K | ★ 1.1M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $12,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | ★ 0.73 | N/A |
| 52 Week Low | $2.01 | $1.39 |
| 52 Week High | $3.75 | $7.19 |
| Indicator | RAVE | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 41.71 |
| Support Level | $3.15 | $1.48 |
| Resistance Level | $3.40 | $1.68 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 21.17 | 21.21 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.